NCT06828289 · NOT YET RECRUITING
Rivastigmine Mini-Tablet for Alzheimer's Disease
This study is testing a new mini-tablet form of rivastigmine, a medication already used for Alzheimer's, to see if it works as well as or better than donepezil, another existing Alzheimer's drug. Researchers are measuring both effectiveness and safety in people with mild to moderate Alzheimer's. The phase is unspecified, so it is unclear how early or late in the development process this sits.
Eligibility criteria
Inclusion Criteria: * Age 50 or older * Meet the National Institute of Aging-Alzheimer's Association clinical criteria for probable Alzheimer's disease * Have a Mini-Mental State Examination score of 10 to 24 at Screening and Baseline * Geriatric Depression Scale score \<=7 at Screening * Hachinski Ischemic Scale \<=4 at Screening * Brain MRI should meet: no infarcts in key areas (thalamus, hippocampus, entorhinal cortex, perirhinal cortex, angular gyrus, etc.), ≤ 2 stroke lesions > 1.5 cm in diameter, and Fazekas Scale - assessed white matter lesion grade * 2. * Patients whose caregivers are well-informed about the patients' condition and, if possible, live with them. * Provide written informed consent Exclusion Criteria: * Any systemic or neurological condition that could contribute to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease * Any psychiatric diagnosis or symptoms (hallucinations, major depression, delusions, etc) interfering with study procedures * An advanced, severe or unstable disease of any type (cardiac, respiratory, gastrointestinal, renal disease, etc) that may interfere with efficacy evaluations * Subjects treated with medication for dementia two weeks prior to baseline
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-02-20